Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Affectis Pharmaceuticals AG

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders, especially depression and schizophrenia. The Company started operations in November 2003 and is located on the premises of the Max-Planck-Institute of Psychiatry (MPI) in Munich, Germany. Affectis has unique capabilities to discover and develop drugs based on pioneering findings in the field of psychiatric disorders. The Company’s drug discovery programme targets two interrelated pathways so far unknown in the context of depression and schizophrenia. Today’s antidepressant market is dominated by therapeutic concepts that are decades old. Shortcomings of existing drugs range from delayed onset of action to a significant rate of non-responders. Affectis’ discovery programmes carry the promise to develop entirely new classes of antidepressant drugs that act fast and in a large number of patients.

Details


Adresse:
Affectis Pharmaceuticals AG

Kraepelinstrasse 2
80804 München
Deutschland
Arbeitsgebiet:
Forschung & Lehre
Sonstige Tätigkeitsfelder
Expansion:
national
Webseite:
Mitarbeiteranzahl:
11-50
Gründungsjahr:
2002